Skip Navigation

Annals of Oncology 2007 18(Supplement 6):vi53-vi57; doi:10.1093/annonc/mdm225
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Adamo, V
Right arrow Articles by Caristi, N
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Adamo, V
Right arrow Articles by Caristi, N
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

breast and ovarian cancer

Overview and new strategies in metastatic breast cancer (MBC) for treatment of tamoxifen-resistant patients

V Adamo*, M Iorfida, E Montalto, V Festa, C Garipoli, A Scimone, M Zanghì and N Caristi

Department of Human Pathology, Medical Oncology and Integrated Therapies Unit, Policlinic Universitary "G. Martino" of Messina, Italy

* Correspondence to: Dr V. Adamo, U.O. Oncologia Medica e Terapie Integrate, A.O. Universitraria Policlinico G. Martino, via consolare valeria n.1, 98125 Messina, Italy. Tel: +390902213238; Fax: +390902213669; E-mail: adamovi{at}libero.it

The treatment with aromatase inhibitors (AIs) and fulvestrant has been demonstrated to be active in a proportion of tamoxifen-resistant breast cancer patients, obtaining, in some cases, a long-term control of tumor growth. Results from clinical trials indicate that treatment with fulvestrant might either precede or follow AIs. However, the AIs are now replacing tamoxifen as first-line advanced and adjuvant therapies, and thus, other options following tamoxifen failure are required. Fulvestrant may be effective in this setting, even if there is also evidence of a lack of cross-resistance between nonsteroidal and steroidal AIs, resulting in the potential use of steroidal AIs following nonsteroidal AI failure and vice versa.

Resistance mechanisms to these therapies appear to be related to a cross talk between estrogen receptor (ER) and growth factor-signaling cascades. Novel therapeutic approaches for ER+ patients, which combine hormonal agents and signal transduction inhibitors, have been developed to overcoming resistance. Several trials are now investigating signal transduction inhibitors combined with endocrine agents. This approach might provide efficient treatments and delay the onset of antihormone resistance, thereby significantly improving patient's survival.

Key words: metastatic breast cancer, new strategies, overview, resistance, tamoxifen, treatment


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.